瑞巴派特联合泮托拉唑治疗幽门螺杆菌阴性慢性糜烂性胃炎的临床疗效及药学分析  

Clinical efficacy and pharmaceutical analysis of rebamipide combined with pantoprazole in the treatment of Helicobacter pylori-negative chronic erosive gastritis

作　　者：辛承益 张劲 王颖[3] 王法[4] XIN Chengyi;ZHANG Jin;WANG Ying;WANG Fa(Department of Pharmacy,Bayannur Hospital,Inner Mongolia,Bayannur 015000,China;Pharmacy Department of Baotou Cancer Hospital,Inner Mongolia,Baotou 014000,China;Department of General Medicine,the First Affiliated Hospital of Hainan Medical University,Hainan,Haikou 570102,China;Department of Operation and Anesthesia,Bayannur Hospital,Inner Mongolia,Bayannur 015000,China)

机构地区：[1]内蒙古自治区巴彦淖尔市医院药剂科,内蒙古巴彦淖尔015000 [2]内蒙古自治区包头市肿瘤医院药剂科,内蒙古包头014000 [3]海南医学院第一附属医院全科医学科,海南海口570102 [4]内蒙古自治区巴彦淖尔市医院手麻科,内蒙古巴彦淖尔015000

出　　处：《中国医药科学》2024年第1期125-128,共4页China Medicine And Pharmacy

摘　　要：目的研究瑞巴派特联合泮托拉唑治疗幽门螺杆菌(Hp)阴性慢性糜烂性胃炎的临床疗效。方法选取巴彦淖尔市医院2020年3月至2023年1月收治的85例Hp阴性慢性糜烂性胃炎患者开展试验。将其按照信封法随机分为试验组42例及参考组43例。试验组予以瑞巴派特联合泮托拉唑治疗,参考组则予以瑞巴派特联合硫糖铝治疗。比较两组临床疗效,比较治疗前后胃黏膜丙二醛(MDA)及前列腺素E_(2)(PGE_(2))水平、血清学指标水平、不良反应。结果试验组治疗总有效率高于参考组(P<0.05)。治疗前两组MDA及PGE_(2)水平比较,差异无统计学意义(P>0.05);治疗8周后,试验组MDA水平低于参考组,而PGE_(2)水平高于参考组,差异有统计学意义(P<0.05)。治疗前两组血清血管活性肠肽(VIP)、胃促生长素(Ghrelin)水平比较,差异无统计学意义(P>0.05);治疗8周后,试验组血清VIP水平低于参考组,而Ghrelin水平高于参考组(P<0.05)。试验组不良反应总发生率低于参考组(P<0.05)。结论瑞巴派特联合泮托拉唑治疗Hp阴性慢性糜烂性胃炎患者的疗效显著,可改善糜烂组织及血清VIP、Ghrelin水平,降低不良反应风险,值得推广应用。Objective To study the clinical efficacy of rebamipide combined with pantoprazole in the treatment of Helicobacter pylori(Hp)-negative chronic erosive gastritis.Methods A trial was conducted on 85 patients with Hp-negative chronic erosive gastritis admitted to Bayannur H ospital from March 2020 to J anuary 2023.They were randomly divided into a trial group of 42 cases and a reference group of 43 cases according to the envelope method.The trial group was treated with rebamipide combined with pantoprazole,while the reference group was treated with rebamipide combined with sucralfate.The clinical efficacy,the levels of malondialdehyde(MDA)and prostaglandin E_(2)(PGE_(2))in the gastric mucosa before and after treatment,the levels of serological indicators before and after treatment,and adverse reactions of the two groups were compared.Results The total effective rate of the trial group was higher than that of the reference group(97.62%vs.83.72%)(P<0.05).There was no statistically significant difference in MDA and PGE_(2) levels between the two groups before treatment(P>0.05).After 8 weeks of treatment,the MDA level in the trial group was lower than that in the reference group,while the PGE_(2) level was higher than that in the reference group,with statistically significant differences(P<0.05).There were no statistically significant differences in the levels of serum vasoactive intestinal peptide(VIP)and ghrelin between the two groups before treatment(P>0.05).After 8 weeks of treatment,the serum VIP level in the trial group was lower than that in the reference group,while the ghrelin level was higher than that in the reference group(P<0.05).The total incidence of adverse reactions in the trial group was lower than that in the reference group(4.76%vs.18.60%)(P<0.05).Conclusion The combination of rebamipide and pantoprazole has a significant efficacy on patients with Hp-negative chronic erosive gastritis,which can improve the levels of VIP and ghrelin in erosive tissues and serum,reduce the risk of adverse reactions,and

关 键 词：慢性糜烂性胃炎 幽门螺杆菌 瑞巴派特 泮托拉唑 疗效 

分 类 号：R573.3[医药卫生—消化系统]